SUVENPHAR2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member SUVENPHAR2021-04-012021-06-30in-bse-fin:OneOperatingExpenses02Member SUVENPHAR2021-04-012021-06-30in-bse-fin:OneOperatingExpenses03Member SUVENPHAR2021-04-012021-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares SUVENPHAR 2021-04-01 2022-03-31 2021-08-06 INR Lakhs First quarter Single segment Contract Development and ManufacturingnOperations (CDMO) 2021-04-01 2021-06-30 Unaudited Consolidated 2638013000.00 57829000.00 2695842000.00 918396000.00 0.00 -150891000.00 211589000.00 21255000.00 89933000.00 512825000.00 1603107000.00 1092735000.00 0.00 1092735000.00 271635000.00 6759000.00 278394000.00 0.00 814341000.00 0.00 0.00 0.00 236490000.00 1050831000.00 -2093000.00 1048738000.00 0.00 0.00 254565000.00 1 4.13 4.13 0.00 0.00 4.13 4.13 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August,2021 . The above results have been subjected to limited review by the statutory auditors of the company. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the wholly owned subsidiary Suven Pharma, Inc., USA and associate Rising Pharma Holdings, Inc., USA 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5) The COVID-19 continuous to impact the business and research operations in India, like increase in some of the rawmaterial costs, non availability of vessels leading to delay in shipments and increase in transportation costs. However, there was no major impact on our subsidiary, Suven pharma, Inc., USA. 6) The Board has alloted Bonus shares at 1:1 ratio in it's Board meeting held on 29th September, 2020. Accordingly the number of shares has increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of the previous periods have been restated. The paidup caputal on account of Bonus issue of Rs.1272.82 Lakhs has been appropriated from the share premium account. 7) The corresponding previous period figures have been regrouped/reclassified where ever necessary. Manufacturing Expenses 388483000.00 Other Expenses 100818000.00 R & D expenses 23524000.00